JAC Advance Access originally published online on August 8, 2006
Journal of Antimicrobial Chemotherapy 2006 58(4):768-772; doi:10.1093/jac/dkl332
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria
1 UMR 8525 CNRS-Universíté de Lille 2 Lille, F-59021, France 2 U629 INSERM-Institut Pasteur de Lille F-59021, France
Received 16 May 2006; returned 14 June 2006; revised 4 July 2006; accepted 18 July 2006
*Corresponding author. Tel: +33-320-87-11-55; Fax: +33-320-87-11-58; E-mail: Alain.Baulard{at}pasteur-lille.fr
Background: Ethionamide is one of the most widely used drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB). Like isoniazid, and pyrazinamide, ethionamide is a prodrug that needs to be activated by a mycobacterial enzyme. Activation pathways of prodrugs are generally problematic to uncover as they produce intermediates potentially difficult to characterize, to purify and that might prove unstable outside of their cellular context.
Objectives and methods: We have used high resolution magic angle spinning-NMR (HRMAS-NMR) to follow ethionamide activation directly within living mycobacterial cells.
Results: Data indicated that the intracellular metabolization of ethionamide strictly depends on the presence of the monooxygenase EthA and that EthA-dependent activation of ethionamide is coupled to a precise molecular sorting mechanism of the ethionamide metabolites. We found that the previously identified ethionamide metabolite 2-ethyl-4-hydroxymethylpyridine is produced in substantial amounts by the ethionamide-treated mycobacteria and that it is present exclusively outside of the bacteria. In contrast, the still unidentified ethionamide metabolite ETH* is the only ethionamide derivative detected within the bacterial cell. Moreover, ETH* appears to be unable to cross the bacterial envelope and consequently accumulates within the cytoplasm of the ethionamide-treated mycobacteria.
Conclusions: These results strongly suggest that ETH* is the active antimycobacterial ethionamide derivative and open new perspectives for the understanding of the mode of action of prodrugs.
Keywords: HRMAS-NMR , thioamide , tuberculosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Maes, C. Mille, X. Trivelli, G. Janbon, D. Poulain, and Y. Guerardel Molecular Phenotyping of Mannosyltransferases-Deficient Candida albicans Cells by High-Resolution Magic Angle Spinning NMR J. Biochem., April 1, 2009; 145(4): 413 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Weber, R. Schoenmakers, B. Keller, M. Gitzinger, T. Grau, M. Daoud-El Baba, P. Sander, and M. Fussenegger A synthetic mammalian gene circuit reveals antituberculosis compounds PNAS, July 22, 2008; 105(29): 9994 - 9998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. R. Merry and C. M. Ward A sugar rush for developmental biology Development, April 15, 2008; 135(8): 1389 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kordulakova, Y. L. Janin, A. Liav, N. Barilone, T. Dos Vultos, J. Rauzier, P. J. Brennan, B. Gicquel, and M. Jackson Isoxyl Activation Is Required for Bacteriostatic Activity against Mycobacterium tuberculosis Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3824 - 3829. [Abstract] [Full Text] [PDF]
|
|